

November 27, 2018

Listing Department  
**BSE LIMITED**  
P J Towers, Dalal Street, Fort,  
Mumbai-400 001

**Code: 532 321**

Listing Department  
**NATIONAL STOCK EXCHANGE OF INDIA LIMITED**  
Exchange Plaza, Bandra Kurla Complex,  
Bandra (E),  
Mumbai-400 051

**Code: CADILAHC**

**Re.: Press Release.**

Dear Sir / Madam,

Please find enclosed a copy of press release dated November 27, 2018 titled "Zydus receives final approval from the USFDA for Baclofen Tablets".

The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking you,

Yours faithfully,

For, **CADILA HEALTHCARE LIMITED**



**UPEN H. SHAH**  
**COMPANY SECRETARY**



**Encl.: As above**

## **Zydus receives final approval from the USFDA for Baclofen Tablets**

*Ahmedabad, 27 November, 2018*

Zydus Cadila has received the final approval from the USFDA to market Baclofen Tablets (US RLD- Lioresal®), 10 mg and 20 mg. It will be manufactured at the group's formulations manufacturing facility at Baddi. Baclofen is used to treat muscle spasms caused by certain conditions such as multiple sclerosis, spinal cord injury/disease. It works by helping to relax the muscles.

The group now has 234 approvals and has so far filed over 340 ANDAs since the commencement of the filing process in FY 2003-04.

### **About Zydus Cadila**

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs over 23,000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020.

\*\*\*